Proactive Investors - Run By Investors For Investors

Japanese drugmaker Takeda sounds out possible lenders as it edges closer to US$50bn bid for Shire

According to two Reuters sources with direct knowledge of the matter, Takeda has spoken with several banks about borrowing tens of billions of dollars to fund the possible acquisition of Shire
microscope in laboratory
If the deal goes through, it will likely be the largest overseas acquisition ever by a Japanese company

Takeda Pharmaceutical has moved a step closer to lodging a US$50bn bid for Shire PLC (LON:SHP) after reports emerged that Japan’s largest drugmaker has sounded out its major creditors for loans to help fund the deal.

Buying Shire would be transformational for Takeda, which believes a deal would strengthen its core therapeutic areas of oncology, gastroenterology and neuroscience, while Shire’s rare disease franchise would also boost its position in specialised medicines.

READ: Takeda considers takeover offer for Shire

But it won’t be easy, and any deal would be a huge financial stretch, given that Shire is worth around US$10bn more than the Japanese group.

Shire first told investors about Takeda’s interest at the end of March and expectations that a bid will be lodged before the April 25 deadline have mounted since Takeda’s boss Christophe Weber held a meeting with analysts about the deal last week.

At that briefing, which was closed to journalists, Weber said that Takeda was mulling a takeover offer for all of Shire and that there was scope to increase debt, according to analysts.

According to two Reuters sources with direct knowledge of the matter, the Japanese drugs giant has now sounded out creditors, including its main bank Sumitomo Mitsui Banking Corp.

Reports in Japan have suggested that Takeda is looking for loans of several trillion yen – equivalent to tens of billions of dollars – in total from several banks.

Representatives for Takeda, Shire and Sumitomo Mitsui Banking Corp were not immediately available for comment.

Shire shares were up 2.1% to £36.65 in early afternoon trade, and they have now gained almost 25% since news of Takeda’s interest first broke.

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use